Overview
Bariendo connects patients with a curated network of elite endobariatric physicians to offer non-surgical weight loss procedures, mainly ESG and related options. The platform provides upfront pricing, 12 months of follow-up care, and financing to simplify access to care; it also includes a smart web app to manage appointments and track progress. ESG Stomach Tightening is a minimally invasive, scar-free procedure performed via an endoscope that reduces stomach size by about 70% in under an hour, with same-day discharge and a short recovery. Bariendo emphasizes standardizing protocols through a scientific advisory board and aims to establish a national standard of care, broaden access to safe, minimally invasive obesity treatment, and grow its clinician network.
Work here?Claim your company
Simplify's take
What believers are saying
- Fractyl said Everself doubled from 15 to 30 centers in 2026.
- The 2025 $11.1 million raise funded expansion before the current center-count jump.
- Driving GLP-1 off-ramp demand in Dallas and Tampa creates immediate patient acquisition tailwinds.
What critics are saying
- Fractyl’s Everself partnership depends on FDA approval, delaying revenue until late 2026.
- Boston Scientific and Apollo already compete with OverStitch-based ESG programs inside Everself’s core market.
- If reimbursement tightens or Revita disappoints, Everself becomes a small procedure marketplace with weak moat.
What makes Everself unique
- Everself standardizes ESG through elite physicians and a national endobariatric protocol.
- Dr. Thompson’s Harvard-pioneered ESG credibility still anchors Everself’s clinical brand.
- The 2026 Fractyl LOI positions Everself as a distribution network for post-GLP-1 procedures.
Help us improve and share your feedback! Did you find this helpful?